2025
Titration and discontinuation of semaglutide for weight management in commercially insured US adults
Xu Y, Carrero J, Chang A, Inker L, Zhang D, Mukhopadhyay A, Blecker S, Horwitz L, Grams M, Shin J. Titration and discontinuation of semaglutide for weight management in commercially insured US adults. Obesity 2025, 33: 1243-1248. PMID: 40464214, PMCID: PMC12213178, DOI: 10.1002/oby.24315.Peer-Reviewed Original ResearchConceptsDose escalation scheduleHigher discontinuation rateDiscontinuation ratesWeight managementMultivariate Cox regressionUS adultsAssociated with discontinuationCommercially insured adultsEarly discontinuationAssociated with low household incomeCox regressionSemaglutideLowest quintileHighest quintileDelivery of evidence-based careLower household incomeMonthsEvidence-based careCopayment amountQuintileAdultsReduce financial barriersDiscontinuationEducation levelIdentified factors
2023
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel J, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko J, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon K, Goetz M, Haddad T, Iwata H, Jassem J, Lee S, Linderholm B, Los M, Mamounas E, Miller K, Morris P, Munzone E, Gal-Yam E, Ring A, Shepherd L, Singer C, Thomssen C, Tseng L, Valagussa P, Winer E, Wolff A, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck A, DeMichele A, Gnant M, Cameron D, El-Abed S, Rugo H, Steger G, Traina T, Werutsky G, Wolmark N. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. Journal Of Clinical Oncology 2023, 41: 5118-5130. PMID: 37556775, DOI: 10.1200/jco.23.00126.Peer-Reviewed Original ResearchConceptsImpact of BMIPALLAS trialBMI categoriesHigher BMIEarly hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerAddition of palbociclibEfficacy of palbociclibEarly treatment discontinuationRelative dose intensityTreatment discontinuation ratesDisease-free survivalSide effect profileMultivariable logistic regressionBreast cancer riskSignificant decreaseNeutropenia ratesPalbociclib armEndocrine therapyTreatment discontinuationDiscontinuation ratesDose intensityEarly discontinuationNormal weight
2022
Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer.
Kier M, Li Z, Casasanta N, Patel R, Agarwal P, Zimmerman B, Yang Y, Fink M, Zhou X, Newman S, Chen R, Schadt E, Oh W, Tiersten A. Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer. Journal Of Clinical Oncology 2022, 40: 523-523. DOI: 10.1200/jco.2022.40.16_suppl.523.Peer-Reviewed Original ResearchRate of discontinuationSupportive therapyBreast cancerAI therapyDiscontinuation ratesSocioeconomic disparitiesInsurance coverageEarly-stage hormone receptor-positive breast cancerSide effectsExact testHormone receptor-positive breast cancerAdjuvant aromatase inhibitor therapyReceptor-positive breast cancerHormone-positive breast cancerInitial AI therapyAromatase inhibitor therapyRetrospective chart reviewMajority of patientsPositive breast cancerBreast cancer survivalFisher's exact testLow socioeconomic statusAdjuvant AIPrimary languageEarly discontinuationImpact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes
Zeidan AM, Joshi N, Kale H, Wang WJ, Corman S, Salimi T, Epstein RS. Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 670-679. PMID: 35614009, DOI: 10.1016/j.clml.2022.04.016.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeHMA therapyPoor performance statusRate of hospitalizationSEER-Medicare databaseMyelodysplastic syndromeER visitsEarly discontinuationPerformance statusEmergency roomOlder agePredictors of discontinuationEmergency room visitsHigh-risk groupHigh economic burdenTreatment discontinuationExcess blastsMore hospitalizationsNew hospitalizationRefractory anemiaRoom visitsHigh riskDiscontinuationMD diagnosisAgent useTreatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele A. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). Journal Of Clinical Oncology 2022, 40: 449-458. PMID: 34995105, PMCID: PMC9851679, DOI: 10.1200/jco.21.01918.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansNeoplasm StagingPiperazinesProtein Kinase InhibitorsPyridinesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRisk FactorsTime FactorsConceptsInvasive disease-free survivalAdjuvant endocrine therapyHuman epidermal growth factor receptorEndocrine therapyEpidermal growth factor receptorPalbociclib exposureGrowth factor receptorBreast cancerHormone Receptor-Positive/Human Epidermal Growth Factor ReceptorAddition of palbociclibNovel adjuvant treatmentDisease-free survivalEarly breast cancerFactor receptorOral cancer therapyProtocol analysisPALLAS studyAdjuvant treatmentEarly discontinuationAdjuvant studiesDiscontinuation ratesDose modificationAnalysis populationCDK4/6 inhibitorsDrug persistence
2021
Neurology trial registrations on ClinicalTrials.gov between 2007 and 2018: A cross-sectional analysis of characteristics, early discontinuation, and results reporting
Turner BE, Magnani CJ, Frolov A, Weeks BT, Steinberg JR, Huda N, Shah LM, Zuroff L, Gu BJ, Rasmussen H, Edwards JG, Save AV, Shen M, Ren M, Bryant BR, Ma Q, Feng AY, Liang AC, Santini VE. Neurology trial registrations on ClinicalTrials.gov between 2007 and 2018: A cross-sectional analysis of characteristics, early discontinuation, and results reporting. Journal Of The Neurological Sciences 2021, 428: 117579. PMID: 34332371, DOI: 10.1016/j.jns.2021.117579.Peer-Reviewed Original ResearchConceptsEarly discontinuationClinical trialsTrial characteristicsNeurological disease burdenMultivariable logistic regressionCross-sectional analysisGovernment-funded trialsYear of completionMultivariable analysisCox regressionTreatment optionsDisease burdenHigher oddsTrial completionClinical careDiscontinuationLower riskAcademic trialsNeurology clinical trialsGreater riskLogistic regressionComparison trialEvidence baseTrialsTherapeutic focusPredictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.
Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes. Journal Of Clinical Oncology 2021, 39: 7043-7043. DOI: 10.1200/jco.2021.39.15_suppl.7043.Peer-Reviewed Original ResearchPoor performance statusPoor PSHigh-risk myelodysplastic syndromeHMA therapyReal-world studyMyelodysplastic syndromeProgression/unacceptable toxicityPills/dayRetrospective cohort studyTreatment-related factorsMultivariable logistic regressionDirect medical costsHigh-risk groupOne-thirdGCSF useMore comorbiditiesEarly discontinuationPerformance statusUnacceptable toxicityCohort studyExcess blastsMultivariable analysisRefractory anemiaSEER-MedicareSurvival outcomesMedication strategies in first episode psychosis patients: A survey among psychiatrists
Kikkert M, Veling W, de Haan L, Begemann M, de Koning M, Sommer I, de Haan L, Veling W, van Os J, Smit F, Begemann M, Schuite‐Koops S, Marcelis M, Kikkert M, van Beveren N, Boonstra N, Rosema B, Bakker P, Gülöksüz S, Lokkerbol J, Brand B, Gangadin S, Geraets C, Hag E, Oomen P, Voppel A, van Amelsvoort T, Bak M, Been A, van den Bosch M, van den Brink T, Faber G, Grootens K, de Jonge M, Knegtering H, Kurkamp J, Mahabir A, Pijnenborg G, Staring T, Vaes W, Veen N, Veerman S, Wiersma S, Sommer I. Medication strategies in first episode psychosis patients: A survey among psychiatrists. Early Intervention In Psychiatry 2021, 16: 139-146. PMID: 33754470, PMCID: PMC9292219, DOI: 10.1111/eip.13138.Peer-Reviewed Original ResearchConceptsFirst psychotic episodeMedication discontinuationMedication strategiesPsychotic episodeFirst-episode psychosis patientsEpisode psychosis patientsSubstantial practice variationFirst-episode patientsMonths of remissionFirst-episode psychosisSpecific treatment strategiesSubsample of patientsPractice of cliniciansMaintenance therapyEarly discontinuationPsychosis patientsAntipsychotic drugsEpisode psychosisTreatment strategiesReduced dosePractice variationLong-term effectsSame doseDiscontinuationMost guidelines
2020
Early discontinuation of pharmacotherapy in U.S. veterans diagnosed with PTSD and the role of psychotherapy
Duek O, Pietrzak RH, Petrakis I, Hoff R, Harpaz-Rotem I. Early discontinuation of pharmacotherapy in U.S. veterans diagnosed with PTSD and the role of psychotherapy. Journal Of Psychiatric Research 2020, 132: 167-173. PMID: 33126010, DOI: 10.1016/j.jpsychires.2020.10.005.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderRisk factorsEarly discontinuationMedication discontinuationPsychotropic medicationsPoor medication adherenceSimilar risk factorsStrong risk factorDeterminants of discontinuationKey risk factorsRole of psychotherapySingle medicationMedication adherenceMedication treatmentPsychiatric comorbidityAntipsychotic medicationPatient educationDiscontinuationOlder veteransMedicationsAdjunctive psychotherapyYounger veteransEarly interventionU.S. veteransVA treatment
2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practicesEarly Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease
Truta B, Leeds IL, Canner JK, Efron JE, Fang SH, Althumari A, Safar B. Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019, 26: 1110-1117. PMID: 31670762, DOI: 10.1093/ibd/izz250.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseIFX groupDisease activityIFX discontinuationSteroid prescriptionEarly discontinuationPregnancy outcomesPreterm babiesBowel diseaseRisk babiesPregnant womenTruven Health Analytics MarketScan databaseContinuation of infliximabMore preterm babiesAcute respiratory infectionsPoor pregnancy outcomesIntrauterine growth retardationRisk of diseaseDisease flareIBD mothersIBD patientsFetal exposureHospital admissionRespiratory infectionsMarketScan databasePhysician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Journal Of The National Comprehensive Cancer Network 2019, 17: 1194-1202. PMID: 31590152, DOI: 10.6004/jnccn.2019.7314.Peer-Reviewed Original ResearchConceptsRituximab discontinuationRituximab initiationHodgkin's lymphomaRelative riskPhysician experienceHigh-quality cancer careOlder adultsInitiation of rituximabEarly treatment discontinuationInfusion-related reactionsPopulation-based studySEER-Medicare dataNon-Hodgkin lymphomaModified Poisson regressionCancer treatment outcomesEarly discontinuationTreatment discontinuationAnticancer immunotherapyPhysician volumeCancer careImproved outcomesOncologists' experiencesTreatment outcomesDiscontinuationRituximab
2018
Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis
Zeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis. Blood 2018, 132: 370. DOI: 10.1182/blood-2018-99-111052.Peer-Reviewed Original ResearchHMA cyclesOverall survivalHMA initiationHMA therapyMyelodysplastic syndromeProvider typeCancer CenterMD volumeMultivariate Cox proportional hazardsKaplan-Meier log-rank testAZA-001 trialMedian overall survivalTwo-sided statistical testsLog-rank testReal-world survivalCox proportional hazardsLogistic regression analysisWilcoxon rank sum testChi-square testCommunity-based practiceRank sum testEligible ptsLookback periodEarly discontinuationAgent therapy
2017
Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease
Feagins LA, Waljee A, Hou JK, Gu P, Kanjo S, Rudrapatna V, Cipher DJ, Govani S, Gaidos J. Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017, 23: 1434-1439. PMID: 28570429, DOI: 10.1097/mib.0000000000001145.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBiological therapyAdverse drug reactionsConcomitant thiopurinesPrimary nonresponseEarly discontinuationBowel diseaseDrug reactionsDiagnosis of IBDBiological agentsFirst biological agentRetrospective cohort studyInitiation of therapyCourse of therapyVA hospital systemIleocolonic diseaseVA cohortCohort studyVeteran patientsMedical recordsRisk factorsCommon reasonPatientsDiscontinuationTherapyPhysician volume and discontinuation of rituximab during lymphoma treatment.
Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly discontinuationRituximab discontinuationPhysician volumeProvider volumeEnd Results-Medicare dataB-cell non-Hodgkin lymphomaCell non-Hodgkin lymphomaCox proportional hazards modelDiscontinuation of rituximabSevere infusion reactionsRetrospective cohort studyImpact of discontinuationDays of initiationProportional hazards modelDose-dependent mannerRituximab cyclesRituximab initiationInfusion reactionsOverall survivalCohort studyPrimary outcomeSystemic treatmentLymphoma treatmentRelative risk
2016
Sa1885 Incidence of and Predictors for Early Discontinuation of Biologic Therapies in Veteran Patients with Inflammatory Bowel Disease
Feagins L, Waljee A, Hou J, Gu P, Kanjo S, Rudrapatna V, Ellis A, Govani S, Gaidos J. Sa1885 Incidence of and Predictors for Early Discontinuation of Biologic Therapies in Veteran Patients with Inflammatory Bowel Disease. Gastroenterology 2016, 150: s392. DOI: 10.1016/s0016-5085(16)31374-9.Peer-Reviewed Original Research
2014
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal Of Clinical Oncology 2014, 33: 13-21. PMID: 25092775, PMCID: PMC4268249, DOI: 10.1200/jco.2014.57.0572.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinCyclophosphamideDose-Response Relationship, DrugDoxorubicinDrug Administration ScheduleFatigueFemaleHumansHypertensionMiddle AgedNeoadjuvant TherapyNeoplasm StagingNeutropeniaPaclitaxelRemission InductionThrombocytopeniaTreatment OutcomeTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerPathologic complete responseNeoadjuvant chemotherapyBreast/axillaStage IIBreast cancerPathologic complete response rateRandomized phase II trialAddition of carboplatinDose-dense doxorubicinRole of carboplatinComplete response ratePhase II trialStandard neoadjuvant chemotherapyThird of patientsAdjuvant trialsConcurrent carboplatinSkipped dosesWeek paclitaxelEarly discontinuationII trialPostoperative complicationsThromboembolic eventsDose modificationOverall survivalCardiovascular events, early discontinuation of trastuzumab, and their impact on survival
Wang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP, Chen J. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Research And Treatment 2014, 146: 411-419. PMID: 24951268, DOI: 10.1007/s10549-014-3029-0.Peer-Reviewed Original ResearchConceptsCardiovascular eventsEarly discontinuationTrastuzumab treatmentCause mortalityTrastuzumab therapyTrastuzumab discontinuationBreast cancerCox proportional hazards modelContinuous trastuzumab treatmentAdverse cardiovascular eventsPopulation-based cohortFemale Medicare beneficiariesHigher mortality riskProportional hazards modelNon-significant increaseCardiovascular complicationsOlder patientsOverall survivalHeart failureAtrial fibrillationDiscontinuationMortality riskOlder womenMedicare beneficiariesHazards modelFrailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901
Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS. Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901. Journal Of Clinical Oncology 2014, 32: 2318-2327. PMID: 24934786, PMCID: PMC4105485, DOI: 10.1200/jco.2013.51.7367.Peer-Reviewed Original ResearchConceptsAdjuvant hormonal therapyHormonal therapyBreast cancerOlder womenInfluence of frailtyCovariate adjustmentRisk of discontinuationNonmetastatic breast cancerBreast cancer ageProportional hazards modelIIB diseaseEarly discontinuationMost patientsOlder patientsProspective cohortBaseline frailtyCancer ageHigher oddsDiscontinuationHazards modelMost womenPsychosocial dataNoninitiationTherapyLogistic regression
2013
Characteristics Associated With Discontinuation of Long-Acting Reversible Contraception Within the First 6 Months of Use
Grunloh D, Casner T, Secura G, Peipert J, Madden T. Characteristics Associated With Discontinuation of Long-Acting Reversible Contraception Within the First 6 Months of Use. Obstetrics And Gynecology 2013, 122: 1214-1221. PMID: 24201685, PMCID: PMC4051392, DOI: 10.1097/01.aog.0000435452.86108.59.Peer-Reviewed Original ResearchConceptsLevonorgestrel intrauterine systemIntrauterine deviceEarly discontinuationCopper intrauterine deviceBaseline characteristicsIntrauterine systemReversible contraceptionFirst-line contraceptive optionRate of discontinuationLong-Acting Reversible ContraceptionLow socioeconomic statusContraceptive CHOICE ProjectMonths of useCohort studyDiscontinuation ratesContraceptive optionsUnintended pregnancyFrequent bleedingDiscontinuationIUD usersCost contraceptionCommon reasonYounger ageLogistic regressionTelephone interviews
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply